How have the shares performed?
Gracell Biotechnologies Inc. (GRCL) saw downtrend of -5.22% in the recent trading with $15.06 being its most recent. The current price level -55.31% lower than the highest price of $33.70 marked by the stock while trading over the past 52-weeks, whereas it is 54.46% higher than the lowest price of $9.75 the company dropped to over past 52-weeks. The latest news story on GRCL appeared in PR Newswire under the title “Gracell Biotechnologies Hosting Key Opinion Leader Webinar on High Risk Multiple Myeloma, Treatment Challenges and Dual-Targeting CAR-T with Overnight Manufacturing – a Novel Approach for Treatment of Multiple Myeloma” on May-26-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -23.71% below one month high and is +54.46% above of the lowest during that time. Looking into the simple moving average, Gracell Biotechnologies Inc. (GRCL)’s stock stands at a SMA-50 of $14.18 while that of 5-day is reading $16.19.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 4 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.50 for the stock.
Gracell Biotechnologies Inc. Earnings – What Happened With GRCL
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Gracell Biotechnologies Inc. (GRCL) last released financial results for the quarter that ended 3/30/2021, posting a surprise factor of -19.00% for net revenue.
GRCL – Gracell Biotechnologies Inc. Stock Earnings Estimates
The perspective of Gracell Biotechnologies Inc. (NASDAQ:GRCL)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.21 for stock’s EPS in the current quarter. 3 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -0.25.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 70.92 million. GRCL does have institutional investors; and they hold 32.60% of the stock.
Gracell Biotechnologies Inc. – Insider Activity and Holdings
As on Mar 30, 2021, Smallcap World Fund was the top most holder in Gracell Biotechnologies Inc. (NASDAQ:GRCL) with an ownership of 1.11 million shares of the company or 1.65% of the stake worth $17.13 million. The filing also reveals Federated Hermes Kaufmann Small Cap Fund as the second largest holder in the company with a control over 0.88% of the outstanding shares. Its stake is worth $12.21 million for having 0.59 million shares in hand.
Federated Hermes Kaufmann Fund also came holding a key position in the company during the recent quarter and it now holds 0.70% of the outstanding shares. With this there are now 13 institutions which have possession in GRCL’s shares.
Currently, the stock has been recommended as Strong Buy by 4 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.50 for the stock.